140 related articles for article (PubMed ID: 14750118)
1. Remission of collapsing focal segmental glomerulosclerosis following chemotherapy for myeloma.
Shah S; Cavenagh J; Sheaf M; Thuraisingham RC
Am J Kidney Dis; 2004 Feb; 43(2):e10-2. PubMed ID: 14750118
[TBL] [Abstract][Full Text] [Related]
2. [Bisphosphonate-induced collapsing focal segmental glomerulosclerosis; two clinical cases and literature review].
Jotterand V; Moll S; Martin PY; Saudan P
Nephrol Ther; 2009 Apr; 5(2):134-8. PubMed ID: 19013118
[TBL] [Abstract][Full Text] [Related]
3. Focal and segmental glomerulosclerosis and plasma cell proliferative disorders.
Dingli D; Larson DR; Plevak MF; Grande JP; Kyle RA
Am J Kidney Dis; 2005 Aug; 46(2):278-82. PubMed ID: 16112046
[TBL] [Abstract][Full Text] [Related]
4. [Improved prognosis of generalized AL-amyloidosis in a patient with multiple myeloma treated according to the VAD protocol].
Sarkisova IA; Rameev VV; Kozlovskaia LV; Andreeva NE
Ter Arkh; 2003; 75(8):81-2. PubMed ID: 14520860
[No Abstract] [Full Text] [Related]
5. [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].
Luo SK; Li J; Hong WD; Zhao Y; Tong XZ
Ai Zheng; 2005 Dec; 24(12):1518-21. PubMed ID: 16351805
[TBL] [Abstract][Full Text] [Related]
6. Fever as presenting symptom of multiple myeloma.
Pitz CC; Lokhorst HM; Hoekstra JB
Neth J Med; 1998 Dec; 53(6):256-9. PubMed ID: 9883003
[TBL] [Abstract][Full Text] [Related]
7. Glomerulonephritis as a Type of Kidney Injury in Multiple Myeloma: a Report of 2 Cases.
Vakili Sadeghi M; Akbari R
Iran J Kidney Dis; 2017 May; 11(3):249-252. PubMed ID: 28575887
[TBL] [Abstract][Full Text] [Related]
8. High dose dexamethasone as first line therapy of multiple myeloma? A case report.
Meregalli M; Bertola G; Grando D
Recenti Prog Med; 1998 Jan; 89(1):18-20. PubMed ID: 9549388
[TBL] [Abstract][Full Text] [Related]
9. Modifications to therapy for multiple myeloma: pegylated liposomal Doxorubicin in combination with vincristine, reduced-dose dexamethasone, and thalidomide.
Hussein MA
Oncologist; 2003; 8 Suppl 3():39-45. PubMed ID: 14671227
[TBL] [Abstract][Full Text] [Related]
10. Assessment of early paraprotein response to vincristine-doxorubicin-dexamethasone chemotherapy may help guide therapy in multiple myeloma.
Ross DM; To LB; Horvath N
Intern Med J; 2004; 34(9-10):576-8. PubMed ID: 15482273
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of focal segmental glomerulosclerosis in association with mantle cell lymphoma.
Wong CF; Mohteshamzadeh M; Arsalanizadeh B; Dutt T; Shawki H; Khine MM; Rustom R
Ren Fail; 2007; 29(3):363-6. PubMed ID: 17497453
[No Abstract] [Full Text] [Related]
12. A prospective study of collapsing focal segmental glomerulosclerosis.
Raja R; Nada R; Yadav AK; Kumar A; Goyal A; Kumar V; Rathi M; Kohli HS; Gupta KL; Sakhuja V; Jha V
Ren Fail; 2016 Jul; 38(6):894-8. PubMed ID: 27266801
[TBL] [Abstract][Full Text] [Related]
13. Podocyte injury associated glomerulopathies induced by pamidronate.
Barri YM; Munshi NC; Sukumalchantra S; Abulezz SR; Bonsib SM; Wallach J; Walker PD
Kidney Int; 2004 Feb; 65(2):634-41. PubMed ID: 14717935
[TBL] [Abstract][Full Text] [Related]
14. Multiple myeloma: biology and therapy.
Barlogie B; Epstein J
J Cancer Res Clin Oncol; 1990; 116(1):109-11. PubMed ID: 2312600
[No Abstract] [Full Text] [Related]
15. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate.
Markowitz GS; Appel GB; Fine PL; Fenves AZ; Loon NR; Jagannath S; Kuhn JA; Dratch AD; D'Agati VD
J Am Soc Nephrol; 2001 Jun; 12(6):1164-1172. PubMed ID: 11373339
[TBL] [Abstract][Full Text] [Related]
16. Melphalan-prednisolone and vincristine-doxorubicin-dexamethasone chemotherapy followed by prednisolone/interferon maintenance therapy for multiple myeloma: Japan Clinical Oncology Group Study, JCOG0112.
Chou T; Tobinai K; Uike N; Asakawa T; Saito I; Fukuda H; Mizoroki F; Ando K; Iida S; Ueda R; Tsukasaki K; Hotta T;
Jpn J Clin Oncol; 2011 Apr; 41(4):586-9. PubMed ID: 21247967
[TBL] [Abstract][Full Text] [Related]
17. [IgD myeloma manifesting as acute renal insufficiency].
Duvic C; Sarret D; De Revel T; Hérody M; Didelot F; Labaye J; Nédélec G
Rev Med Interne; 2000 Sep; 21(9):799-803. PubMed ID: 11039177
[TBL] [Abstract][Full Text] [Related]
18. VAD followed by VMCP: an alternative regimen for multiple myeloma.
Wadhwa J; Kumar L; Kochupillai V
Med Oncol; 2002; 19(2):105-8. PubMed ID: 12180477
[TBL] [Abstract][Full Text] [Related]
19. The treatment of multiple myeloma.
Alexanian R; Dimopoulos M
N Engl J Med; 1994 Feb; 330(7):484-9. PubMed ID: 8289856
[No Abstract] [Full Text] [Related]
20. Is there still place for VAD as primary treatment for patients with multiple myeloma who are candidates for high-dose therapy?
Dimopoulos MA; Kastritis E
Leuk Lymphoma; 2006 Nov; 47(11):2271-2. PubMed ID: 17107895
[No Abstract] [Full Text] [Related]
[Next] [New Search]
